Bryan Baugh

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

Jeffrey L. Lennox, Raphael J. Landovitz, Heather J. Ribaudo et al. · Annals of Internal Medicine · 2014 · 260 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Ighovwerha Ofotokun, Lumine H Na, Raphael J. Landovitz et al. · Clinical Infectious Diseases · 2015 · 82 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Total and unbound darunavir pharmacokinetics in pregnant women infected with <scp>HIV</scp>‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

C D Zorrilla, Rodney Wright, OO Osiyemi et al. · HIV Medicine · 2013 · 50 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pregnancy outcomes and pharmacokinetics in pregnant women living with <scp>HIV</scp> exposed to long‐acting cabotegravir and rilpivirine in clinical trials

Parul Patel, Susan L. Ford, Mark Baker et al. · HIV Medicine · 2022 · 47 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Compassionate use of <scp>long‐acting</scp> cabotegravir plus rilpivirine for people living with <scp>HIV</scp>‐1 in need of parenteral antiretroviral therapy

Ronald D’Amico, Santiago Cenoz Gomis, Riya Moodley et al. · HIV Medicine · 2022 · 46 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +17